KLSE (MYR): ALPHA (0303)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.33
Today's Change
+0.005 (1.54%)
Day's Change
0.32 - 0.33
Trading Volume
5,914,700
Market Cap
1,604 Million
NOSH
4,860 Million
Latest Quarter
31-May-2024 [#4]
Announcement Date
17-Jul-2024
Next Quarter
31-Aug-2024
Est. Ann. Date
17-Oct-2024
Est. Ann. Due Date
30-Oct-2024
QoQ | YoY
3.10% | 0.00%
Revenue | NP to SH
125,990.000 | 39,811.000
RPS | P/RPS
2.59 Cent | 12.73
EPS | P/E | EY
0.82 Cent | 40.29 | 2.48%
DPS | DY | Payout %
0.65 Cent | 1.97% | 79.04%
NAPS | P/NAPS
0.04 | 8.25
QoQ | YoY
54.29% | null%
NP Margin | ROE
32.18% | 20.48%
F.Y. | Ann. Date
31-May-2024 |
Latest Audited Result
Announcement Date
Next Audited Result
Est. Ann. Date
Est. Ann. Due Date
Revenue | NP to SH
167,586.000 | 52,933.000
RPS | P/RPS
3.45 Cent | 9.57
EPS | P/E | EY
1.15 Cent | 30.30 | 3.30%
DPS | DY | Payout %
0.70 Cent | 2.12% | 64.27%
NAPS | P/NAPS
0.04 | 8.25
YoY
null%
NP Margin | ROE
32.26% | 27.23%
F.Y. | Ann. Date
31-May-2024 | 17-Jul-2024
Revenue | NP to SH
167,586.000 | 52,933.000
RPS | P/RPS
3.45 Cent | 9.57
EPS | P/E | EY
1.15 Cent | 30.30 | 3.30%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
1.99% | null%
NP Margin | ROE
32.26% | 27.23%
F.Y. | Ann. Date
31-May-2024 | 17-Jul-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 3 / 4 | 75.00% | 3 / 6 | 50.00% |
Total Positive Profit Years | 3 / 4 | 75.00% | 3 / 6 | 50.00% |
Continuous Quarters Of Positive Profit | 3 / 4 | 75.00% | 3 / 6 | 50.00% |
Continuous Quarters Of Profit Growth | 3 / 4 | 75.00% | 3 / 6 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 3 / 4 | 75.00% | 3 / 6 | 50.00% |
Total Dividend Years | 2 / 4 | 50.00% | 2 / 6 | 33.00% |
Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 6 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 6 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 6 | 0.00% |
Average ROE | 12.75% | 8.50% | ||
Average Net Profit Margin | 24.20% | 16.13% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Positive Profit Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Positive Profit | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Profit Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Dividend Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend Growth | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Average ROE | 13.62% | 13.62% | ||
Average Net Profit Margin | 16.13% | 16.13% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 125,990 | 167,586 | 167,586 | 83,793 | 83,793 |
NP to SH | 39,811 | 52,933 | 52,933 | 26,466 | 26,466 |
Dividend | 31,468 | 34,019 | 34,019 | 17,009 | 17,009 |
Adjusted EPS | 0.82 | 1.15 | 1.15 | 0.58 | 0.58 |
Adjusted DPS | 0.65 | 0.70 | 0.70 | 0.35 | 0.35 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | 14.84% | 0.00% | 0.00% | 48.41% | 122.61% |
NP to Owner | 3.10% | 0.00% | 0.00% | 40.76% | 111.13% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | 3.72% | 0.00% | 0.00% | 41.31% | 111.96% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | -24.82% | 50.36% | 50.36% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
NP to Owner | -24.79% | 50.42% | 50.42% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
Dividend | -7.50% | 85.00% | 85.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
Adjusted EPS | -28.70% | 42.61% | 42.61% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
Adjusted DPS | -7.14% | 85.71% | 85.71% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
This stock is undervalued. Alpha IVF actually is very well-known around the world
2 weeks ago
ALPHA’s in vitro fertilization (IVF) success rates have reached global benchmarks, with the company achieving a remarkable 82.5% pregnancy success rate
2 weeks ago
ALPHA Strong Financial Performance:
• Revenue Growth: Revenue increased from RM62.1 million in FY2021 to RM137.5 million in FY2023, a growth of 121.5%.
• Profit Growth: Net profit soared from RM2.3 million in FY2021 to RM54.8 million in FY2023, a 2,282.6% increase.
• Profit Margins: Gross profit margin increased to 55.8%, and net profit margin surged to 39.9%.
2 weeks ago
Just check, Alpha will further expand its specialist centres in Malaysia, Indonesia, and either Cambodia or Laos, as well as its research and development team, to keep up with the latest developments in assisted reproductive services. Nice!
2 weeks ago
Greater awareness and government support are birthing an IVF boom !https://www.businesstimes.com.sg/companies-markets/consumer-healthcare/greater-awareness-and-government-support-are-birthing-ivf-boom
1 week ago
director eating up the share price at 0.32, push it up slowly with next result
1 week ago
Volum dagangan kian hari kian meningkat. Jangka ALPHA mampu memecah 40 sen pd masa yg akan datang
1 week ago
Any chance Alpha transfer to Main Market soon?
SC Introduces Accelerated Transfer of Listing from ACE Market to Main Market for Eligible ACE Market Companies
Under the new accelerated transfer process, an ACE Market PLC must, among others, have a daily market capitalisation of at least RM1 billion for the past six months, and meet the profit requirements for companies seeking listing on the Main Market.
1 week ago
Alpha IVF’s market capitalisation is currently RM1.55 billion and has remained at this level since its listing. It is very certain that the company can enter the main board within this year
1 week ago
Business is good and ALPHA is expanding into China and Indonesia, establishing new specialized centers, satellite clinics, and sales offices to tap into these large markets.
1 week ago
Management is optimistic about the company’s prospects and ability to sustain growth, especially with the rising number of patients choosing Malaysia for fertility treatments
1 week ago
another week clearing the 0.32 wall, don't forget boss picking up alot at 0.32
1 week ago
Just sharing - A Modern Woman’s Blessing – ALPHA IVF
https://klse.i3investor.com/web/blog/detail/lvblogcn/2024-08-22-story-h-153382853-A_Modern_Woman_s_Blessing_ALPHA_IVF
1 week ago
ALPHA has a 100.0% success rate consecutively in embryo cryopreservation, and has been recognized by the Malaysia Book of Records. It's pro
1 week ago
ALPHA plans to expand into China and Indonesia, establishing more specialized centers and four satellite clinics in major cities across Indonesia, while opening two sales offices in China. Keep growing ALPHA
4 days ago
The eight cornerstone investors in Alpha IVF were abrdn Malaysia Sdn Bhd, AHAM Asset Management Bhd, AIA Bhd, Eastspring Investments Bhd, Hong Leong Asset Management Bhd, Kenanga Investors Bhd, Lion Global Investors Ltd and Value Partners Hong Kong Ltd 😉
4 days ago
Next expansion news - Alpha IVF Group Bhd is venturing into the Philippine medical business, focusing on obstetrics and gynaecology as well as fertility, as it formed a joint-venture with two doctors from that country.
3 days ago
The new center will open in early 2025 and will serve the 115 million population in the Philippines
https://themalaysianreserve.com/2024/09/03/alpha-ivf-expands-to-manila-with-new-ivf-centre/
3 days ago
Am invest buy call, TP 0.42
For small cap ideas, we like fertility specialist Alpha IVF (BUY, FV: RM0.42/share) which continues to deliver remarkably high pregnancy success rates, superior margins and canny focus on target markets amid rising affluence and low IVF penetration rates in the region position ahead of peers
2 days ago
Not merely setting up new medical centres, ALPHA will replicate its IVF laboratories and embryology services and deploy its proprietary system of systems to ensure high pregnancy rates in its new centre in Manila
2 days ago
We buy the business, not stocks. Alpha IVF's business will definitely be good in the future
1 day ago
CASHewnut
wah 0.32 is a hard wall to break
2 weeks ago